CN102924435A - Novel crystal form of S-omeprazole magnesium salt and preparing method thereof - Google Patents
Novel crystal form of S-omeprazole magnesium salt and preparing method thereof Download PDFInfo
- Publication number
- CN102924435A CN102924435A CN2012104828587A CN201210482858A CN102924435A CN 102924435 A CN102924435 A CN 102924435A CN 2012104828587 A CN2012104828587 A CN 2012104828587A CN 201210482858 A CN201210482858 A CN 201210482858A CN 102924435 A CN102924435 A CN 102924435A
- Authority
- CN
- China
- Prior art keywords
- esomprazole
- crystalline form
- magnesium salts
- water
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention provides a crystal form I of S-omeprazole magnesium salt, wherein characteristic peaks exist at the positions with the d values being 15.0 to 15.4, 12.2 to 12.6, 8.8 to 9.2, 8.3 to 8.7, 7.7 to 8.1, 5.5 to 5.7, 5.2 to 5.4, 4.9 to 5.1, 4.8, 4.7, 4.6, 4.2 to 4.4, 4.1, 4.0, 3.7 to 3.9 and 3.3 to 3.7 in a powder X-ray diffraction pattern. The invention also provides a preparing method for the crystal form I of S-omeprazole magnesium salt. The crystal form I has high storage stability and improves redissolving capability at room temperature, and furthermore, the preparing process of the crystal form is simple and has high yield amounting to 92%, so as to improve the utilization rate of the raw material, effectively save the production cost and have excellent industrial application prospect.
Description
Technical field
The present invention relates to the medicine new crystal, particularly, relate to the new crystal of esomprazole magnesium salts, also relate to the preparation method of this crystal formation.
Background technology
Omeprazole is proton pump inhibitor, and the secretion of energy establishment hydrochloric acid in gastric juice can be used for the treatment of stomach ulcer, the disease that prevention is relevant with hydrochloric acid in gastric juice with treatment.
WO94/27988(CN94190335.4) preparation method of omeprazole single enantiomer and magnesium salts thereof is disclosed.Single enantiomer esomprazole and magnesium salts thereof have improved pharmacokinetic properties, reduce individual difference.The package stability specific ionization esomprazole of esomprazole magnesium salts is good.CN02113294.1 provides the method for the synthetic esomprazole magnesium salts of a kind of water, WO1998/054171(CN98805521.X) announced esomprazole magnesium salts trihydrate crystal and preparation method thereof, CN200380107036.X discloses esomprazole magnesium salts that exists with amorphous solid and preparation method thereof.
A kind of different solid forms of active constituents of medicine can have different physico-chemical properties, such as mobile, compressibility and solubleness etc., thereby preparation process and the characteristics such as dissolution rate, bioavailability of active constituents of medicine when making pharmaceutical preparation are exerted an influence.Some new solid forms may be more suitable for a certain formulation, and other form may be more suitable in other different dosage form.Its formulation of improvement that is found to be of new solid form provides possibility.Therefore, it is significant obtaining the new solid form of esomprazole magnesium salts.
Summary of the invention
The object of the present invention is to provide new crystal of esomprazole magnesium salts and preparation method thereof.
The invention provides a kind of crystalline form I of esomprazole magnesium salts, in the powder X-ray ray diffraction diagram, be 15.2 ± 0.2,12.4 ± 0.2,10.9 ± 0.2,8.5 ± 0.2,7.9 ± 0.2,5.6 ± 0.1,5.3 ± 0.1,5.0 ± 0.1,4.8,4.7,4.6,4.3 ± 0.1,4.1,4.0,3.8 ± 0.1 in the d value respectively,
There is characteristic peak at the place.
Further, in the powder X-ray ray diffraction diagram, be 15.2,12.4,10.9,8.5,7.9,5.6,5.3,5.0,4.8,4.7,4.6,4.3,4.1,4.0,3.8 in the d value respectively,
There is characteristic peak at the place.
Further, in the powder X-ray ray diffraction diagram, its characteristic peak is as follows:
Further preferably, the X-ray diffraction of this crystal formation as shown in Figure 1.
The present invention also provides the preparation method of above-mentioned crystalline form I, and it comprises the steps:
A) the esomprazole magnesium salts is dissolved in the Methanol+Water, is stirred to fully dissolving;
B) a) gained solution is concentrated with step, stirs adding acetone under room temperature in concentrated solution, and cooling is left standstill, crystallize out, and isolation of crystalline, vacuum-drying under the room temperature namely gets crystalline form I.
Wherein, step a) in, Methanol+Water is the methyl alcohol of water content 0.5-10%v/v, the weightmeasurement ratio of esomprazole magnesium salts and mixed solvent is 1:8-15; In the step b), the volume ratio of concentrated solution and filtrate is 2-4:10, and the volume ratio of concentrated solution and acetone is 2-4:20.
Further, step a) in, Methanol+Water is the methyl alcohol of water content 2%v/v.
Wherein, the esomprazole magnesium salts prepares by the following method:
Get esomprazole sodium, add the water of 2-8 times of weight, dissolving, stirring lower dropping concentration is the MgCl of 20 ~ 40%w/v
26H
2The O aqueous solution finishes, and continues to stir, and filters, and vacuum-drying gets the esomprazole magnesium salts; Wherein esomprazole sodium and MgCl
26H
2The mol ratio of O is (1.5 ~ 2.5): 1.
Further, the esomprazole magnesium salts prepares by the following method:
Get esomprazole sodium, add the water of 4 times of weight, dissolving, stirring lower dropping concentration is the MgCl of 25 ~ 30%w/v
26H
2The O aqueous solution finishes, and continues to stir, and filters, and vacuum-drying gets the esomprazole magnesium salts; Wherein esomprazole sodium and MgCl
26H
2The mol ratio of O is 1.9 ~ 2.0:1.
Crystalline form I of the present invention at room temperature package stability is good, and solubility strengthens, and the preparation technology of this crystal formation is easy, and yield is high, can reach 92%, has improved the utilization ratio of raw material, has effectively saved production cost, has good prospects for commercial application.
Obviously, according to foregoing of the present invention, according to ordinary skill knowledge and the customary means of this area, not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite, can also make modification, replacement or the change of other various ways.
The embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
Description of drawings
The X-diffracting spectrum of Fig. 1 crystalline form I
Embodiment
The preparation of embodiment 1 crystalline form I of the present invention
Esomprazole magnesium salts 10g adds the methyl alcohol 100ml of water content 2%, stirs and makes dissolve complete.This solution is concentrated into approximately 30ml, under room temperature, stirring, adds acetone 200ml, separate out white solid, put refrigerator overnight.Filter a small amount of washing with acetone filter cake.There is lower greenhouse vacuum-drying in filter cake in Vanadium Pentoxide in FLAKES, gets 9.2g esomprazole magnesium salts crystalline form I.
The X-diffracting spectrum is seen Fig. 1.
The information of characteristic peak is as follows in the X-diffracting spectrum of crystalline form I:
Table 1
The esomprazole magnesium salts can obtain by buying the commercial goods, perhaps prepares by existing method, and for example: get esomprazole sodium 10g, add water 40ml, stirring and dissolving stirs the lower 10ml of dropping and contains 2.8gMgCl
26H
2The aqueous solution of O finishes, and continues to stir 40min.Filter, a small amount of water washing filter cake, vacuum-drying gets the esomprazole magnesium salts.
Comparative Examples
Will with embodiment 1 with batch esomprazole magnesium salts 10g, be dissolved in 100ml methyl alcohol, fully stir, filter, filtrate is concentrated into approximately 30ml, adds acetone 200ml in room temperature, under stirring, and separates out white solid, puts refrigerator overnight.Filter a small amount of washing with acetone filter cake.There is lower greenhouse vacuum-drying in filter cake in Vanadium Pentoxide in FLAKES, gets 8.7gS-magnesium salt of omeprazole crystal formation.
Crystalline form I of the present invention at room temperature package stability is good, and solubility strengthens, and the preparation technology of this crystal formation is easy, and yield is high, can reach 92%, has improved the utilization ratio of raw material, has effectively saved production cost, has good prospects for commercial application.
Claims (9)
1. the crystalline form I of an esomprazole magnesium salts, it is characterized in that, in the powder X-ray ray diffraction diagram, be 15.2 ± 0.2,12.4 ± 0.2,10.9 ± 0.2,8.5 ± 0.2,7.9 ± 0.2,5.6 ± 0.1,5.3 ± 0.1,5.0 ± 0.1,4.8,4.7,4.6,4.3 ± 0.1,4.1,4.0,3.8 ± 0.1 in the d value respectively,
There is characteristic peak at the place.
2. crystalline form I according to claim 1 is characterized in that: in the powder X-ray ray diffraction diagram, be 15.2,12.4,10.9,8.5,7.9,5.6,5.3,5.0,4.8,4.7,4.6,4.3,4.1,4.0,3.8 in the d value respectively,
There is characteristic peak at the place.
3. crystalline form I according to claim 1 and 2, it is characterized in that: in the powder X-ray ray diffraction diagram, its characteristic peak is as follows:
4. the described crystalline form I of any one according to claim 1-3, it is characterized in that: the X-ray diffraction of this crystal formation as shown in Figure 1.
5. the preparation method of the described crystalline form I of claim 1-4 any one, it is characterized in that: it comprises the steps:
A) the esomprazole magnesium salts is dissolved in the Methanol+Water, stirring and dissolving;
B) a) gained solution is concentrated with step, stirs adding acetone under room temperature in concentrated solution, and cooling is left standstill, crystallize out, and isolation of crystalline, vacuum-drying under the room temperature namely gets crystalline form I.
6. described crystalline form I preparation method according to claim 5 is characterized in that: step a) in, Methanol+Water is the methyl alcohol of water content 0.5-10%v/v, the weightmeasurement ratio of esomprazole magnesium salts and mixed solvent is 1:8-15; In the step b), the volume ratio of concentrated solution and filtrate is 2-4:10, and the volume ratio of concentrated solution and acetone is 2-4:20.
7. the preparation method of described crystalline form I according to claim 6 is characterized in that: step a) in, Methanol+Water is the methyl alcohol of water content 2%v/v.
8. the preparation method of described crystalline form I according to claim 5, it is characterized in that: the esomprazole magnesium salts prepares by the following method:
Get esomprazole sodium, add the water of 2-8 times of weight, dissolving, stirring lower dropping concentration is the MgCl of 20 ~ 40%w/v
26H
2The O aqueous solution finishes, and continues to stir, and filters, and vacuum-drying gets the esomprazole magnesium salts; Wherein esomprazole sodium and MgCl
26H
2The mol ratio of O is (1.5 ~ 2.5): 1.
9. the preparation method of described crystalline form I according to claim 8, it is characterized in that: the esomprazole magnesium salts prepares by the following method:
Get esomprazole sodium, add the water of 4 times of weight, dissolving, stirring lower dropping concentration is the MgCl of 25 ~ 30%w/v
26H
2The O aqueous solution finishes, and continues to stir, and filters, and vacuum-drying gets the esomprazole magnesium salts; Wherein esomprazole sodium and MgCl
26H
2The mol ratio of O is 1.9 ~ 2.0:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210482858.7A CN102924435B (en) | 2011-11-25 | 2012-11-23 | Novel crystal form of S-omeprazole magnesium salt and preparing method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110381874 | 2011-11-25 | ||
| CN201110381874.2 | 2011-11-25 | ||
| CN201210482858.7A CN102924435B (en) | 2011-11-25 | 2012-11-23 | Novel crystal form of S-omeprazole magnesium salt and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102924435A true CN102924435A (en) | 2013-02-13 |
| CN102924435B CN102924435B (en) | 2014-06-25 |
Family
ID=47639394
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210483924.2A Active CN102936238B (en) | 2011-11-25 | 2012-11-23 | New crystal form of S-omeprazole magnesium salt and preparation method thereof |
| CN201210482858.7A Active CN102924435B (en) | 2011-11-25 | 2012-11-23 | Novel crystal form of S-omeprazole magnesium salt and preparing method thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210483924.2A Active CN102936238B (en) | 2011-11-25 | 2012-11-23 | New crystal form of S-omeprazole magnesium salt and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102936238B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1367172A (en) * | 2002-01-30 | 2002-09-04 | 成都市药友科技发展有限公司 | Prearation method of [(substituted pyridyl) methyl] sulfinyl-IH-benzimidazole compound magnesium salt |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE510650C2 (en) * | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
| CN101391993B (en) * | 2008-10-28 | 2012-07-04 | 安徽美诺华药物化学有限公司 | Method for preparing S-omeprazole and salt thereof by forming inclusion complex with (S)-(-)-1,1'-dinaphthalene-2,2'-diol |
| CN102241668B (en) * | 2010-05-11 | 2015-11-25 | 中国科学院成都有机化学有限公司 | Esomprazole salt |
| CN102816149B (en) * | 2011-06-10 | 2015-05-13 | 上海汇伦生命科技有限公司 | Preparation method for high-enantioselectivity synthesized (S)-omeprazole and salt thereof |
-
2012
- 2012-11-23 CN CN201210483924.2A patent/CN102936238B/en active Active
- 2012-11-23 CN CN201210482858.7A patent/CN102924435B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1367172A (en) * | 2002-01-30 | 2002-09-04 | 成都市药友科技发展有限公司 | Prearation method of [(substituted pyridyl) methyl] sulfinyl-IH-benzimidazole compound magnesium salt |
Non-Patent Citations (1)
| Title |
|---|
| 崔名全等: "S-奥美拉唑镁的水相法合成研究", 《合成化学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102936238A (en) | 2013-02-20 |
| CN102924435B (en) | 2014-06-25 |
| CN102936238B (en) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105061459B (en) | A kind of preparation method of bisulfate clopidogrel I crystal spheroidal crystal | |
| CN106389374A (en) | Pharmaceutical composition containing LCZ696 and preparation method of pharmaceutical composition | |
| CN101139280B (en) | Preparation method of sodium acetate anhydrous | |
| CN103923110B (en) | There is the preparation method of the benzimidizole derivatives metal complexes of anti-microbial activity | |
| CN101704766A (en) | Preparation method of arginine aspirin and powder-injection of arginine aspirin | |
| CN107216409A (en) | A kind of preparation method of chitosan L malic acid rare earth compoundings | |
| CN102993177B (en) | Preparation method of high-purity esomeprazole sodium salt | |
| CN104844625A (en) | Cefamandole nafate new crystal form and crystallization preparing method thereof | |
| CN102349647A (en) | Combination containing lutein ester and preparation method thereof | |
| CN102924435B (en) | Novel crystal form of S-omeprazole magnesium salt and preparing method thereof | |
| CN103265444A (en) | Crystallization method of 5-aminolevulinic acid phosphate | |
| CN103420979A (en) | Esomeprazole sodium refining method | |
| CN103864690A (en) | S crystal form of ivabradine hydrochloride, and preparation method and pharmaceutical composition thereof | |
| CN103755609B (en) | Crystal formation of tartaric acid valnemulin and preparation method thereof | |
| CN103012536A (en) | Sodium fusidate crystallization method | |
| CN102349875A (en) | Preparation method of methylsulfonic acid imatinib tablet | |
| CN110467586B (en) | Preparation method of flunarizine hydrochloride crystal | |
| CN103044361B (en) | Preparation method of (2R,3S)-epoxidation amino-benzene butane | |
| CN103709141A (en) | Crystal forms and amorphous forms of rabeprazole sodium | |
| CN113620964A (en) | Substituted calixazole derivatives, and synthetic method and application thereof | |
| CN103524365A (en) | Method for preparing lysine ketoprofen | |
| CN104119315B (en) | A kind of preparation method of Sodium rabeprazole | |
| CN104151275A (en) | Preparation method of andrographolide compound | |
| CN105017183B (en) | A kind of method for crystallising of pharmaceutical intermediate | |
| CN101550144A (en) | Preparation technique for mezlocillin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |